May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Effects of a Single Intravitreal Bevacizumab (Avastin) Injection as Treatment of Diabetic Macular Edema
Author Affiliations & Notes
  • M. Khairallah
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • K. Hmidi
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • S. Jenzeri
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • S. Zaouali
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • S. Ben Yahia
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • R. Messaoud
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • Footnotes
    Commercial Relationships  M. Khairallah, None; K. Hmidi, None; S. Jenzeri, None; S. Zaouali, None; S. Ben Yahia, None; R. Messaoud, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5582. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Khairallah, K. Hmidi, S. Jenzeri, S. Zaouali, S. Ben Yahia, R. Messaoud; Effects of a Single Intravitreal Bevacizumab (Avastin) Injection as Treatment of Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5582. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy and safety of a single intravitreal bevacizumab injection as primary treatment of diabetic macular edema (DME).

Methods: : Thirty three eyes (32 patients) with DME received a single injection of intravitreal bevacizumab (1.25 mg/0.05 mL). Visual acuity and central macular thickness (CMT) measured by optical coherence tomography were evaluated at baseline and follow-up visits. Mean follow-up was 5 months (range, 3-12).

Results: : Best-corrected visual acuity improved in 8 eyes (24.2%), remained stable in 15 eyes (45.5%), and decreased in 10 eyes (30.3%). Mean CMT at baseline was 560 +/- 147 µm and decreased to a mean of 464 +/- 208 µm. The CMT remained unchanged in 11 eyes (33.4%). No systemic or ocular adverse events were observed.

Conclusions: : One single injection of intravitreal bevacizumab at dose of 1.25 mg can reduce CMT in some eyes, with or without subsequent improvement in visual acuity. This therapeutic modality appears to be less effective than intravitreal triamcinolone in the short term management of DME in terms of CMT reduction and visual acuity improvement.

Keywords: diabetic retinopathy • macula/fovea • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×